RGNX Relative Valuation
RGNX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RGNX is overvalued; if below, it's undervalued.
Historical Valuation
Regenxbio Inc (RGNX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 2.86. The fair price of Regenxbio Inc (RGNX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：13.58
Fair
-4.73
PE
1Y
3Y
5Y
Trailing
Forward
-55.00
EV/EBITDA
Regenxbio Inc. (RGNX) has a current EV/EBITDA of -55.00. The 5-year average EV/EBITDA is -3.67. The thresholds are as follows: Strongly Undervalued below -23.91, Undervalued between -23.91 and -13.79, Fairly Valued between 6.45 and -13.79, Overvalued between 6.45 and 16.57, and Strongly Overvalued above 16.57. The current Forward EV/EBITDA of -55.00 falls within the Strongly Undervalued range.
-6.97
EV/EBIT
Regenxbio Inc. (RGNX) has a current EV/EBIT of -6.97. The 5-year average EV/EBIT is -5.86. The thresholds are as follows: Strongly Undervalued below -27.05, Undervalued between -27.05 and -16.46, Fairly Valued between 4.73 and -16.46, Overvalued between 4.73 and 15.32, and Strongly Overvalued above 15.32. The current Forward EV/EBIT of -6.97 falls within the Historic Trend Line -Fairly Valued range.
2.74
PS
Regenxbio Inc. (RGNX) has a current PS of 2.74. The 5-year average PS is 5.94. The thresholds are as follows: Strongly Undervalued below -1.00, Undervalued between -1.00 and 2.47, Fairly Valued between 9.41 and 2.47, Overvalued between 9.41 and 12.89, and Strongly Overvalued above 12.89. The current Forward PS of 2.74 falls within the Historic Trend Line -Fairly Valued range.
9.45
P/OCF
Regenxbio Inc. (RGNX) has a current P/OCF of 9.45. The 5-year average P/OCF is -7.96. The thresholds are as follows: Strongly Undervalued below -77.54, Undervalued between -77.54 and -42.75, Fairly Valued between 26.83 and -42.75, Overvalued between 26.83 and 61.62, and Strongly Overvalued above 61.62. The current Forward P/OCF of 9.45 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Regenxbio Inc. (RGNX) has a current P/FCF of 0.00. The 5-year average P/FCF is 1.25. The thresholds are as follows: Strongly Undervalued below -116.75, Undervalued between -116.75 and -57.75, Fairly Valued between 60.26 and -57.75, Overvalued between 60.26 and 119.26, and Strongly Overvalued above 119.26. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Regenxbio Inc (RGNX) has a current Price-to-Book (P/B) ratio of 4.04. Compared to its 3-year average P/B ratio of 1.96 , the current P/B ratio is approximately 105.74% higher. Relative to its 5-year average P/B ratio of 2.21, the current P/B ratio is about 82.55% higher. Regenxbio Inc (RGNX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -29.35%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -17.01% , the current FCF yield is about -100.00% lower.
4.07
P/B
Median3y
1.96
Median5y
2.21
-16.30
FCF Yield
Median3y
-29.35
Median5y
-17.01
Competitors Valuation Multiple
The average P/S ratio for RGNX's competitors is 0.00, providing a benchmark for relative valuation. Regenxbio Inc Corp (RGNX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 22.88%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RGNX increased by 67.92% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.33 to -3.75.
The secondary factor is the Revenue Growth, contributed 22.88%to the performance.
Overall, the performance of RGNX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Regenxbio Inc (RGNX) currently overvalued or undervalued?
What is Regenxbio Inc (RGNX) fair value?
How does RGNX's valuation metrics compare to the industry average?
What is the current P/B ratio for Regenxbio Inc (RGNX) as of Dec 05 2025?
What is the current FCF Yield for Regenxbio Inc (RGNX) as of Dec 05 2025?
What is the current Forward P/E ratio for Regenxbio Inc (RGNX) as of Dec 05 2025?